Mead Johnson Nutrition CO (MJN) Cut to Sell at Zacks Investment Research


According to Zacks, "Mead Johnson posted dismal financial numbers in the third quarter of 2015, missing the Zacks Consensus Estimate of both earnings and revenues.The company's segmental performance was also considerably weak. Moreover, the near-term challenges in its emerging market segments are expected to continue in 2016 as well.



from Biotech News